Rafferty Asset Management
VIVO

Rafferty Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Rafferty Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-311,884
Closed -$4.43M – 714
2018
Q1 		$4.43M Buy
+311,884
New +$4.62M 0.07% 151

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Rafferty Asset Management's VIVO Position: Q2 2018 in Review

Rafferty Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2018, closing a stake of 311,884 shares — an estimated $4.43M sold.

Rafferty Asset Management first reported a position in VIVO in Q1 2018 and held it in 1 quarter. The position peaked at $4.43M in Q1 2018. 177 funds tracked by Wall St. Rank hold VIVO as of Q2 2018.

  • Rafferty Asset Management reported no remaining Meridian Bioscience Inc position as of Q2 2018 after selling out during the quarter.
  • Rafferty Asset Management sold 311,884 Meridian Bioscience Inc shares in Q2 2018, an estimated $4.43M.
  • Rafferty Asset Management first reported a position in Meridian Bioscience Inc in Q1 2018 and held it in 1 quarter.
  • Rafferty Asset Management's Meridian Bioscience Inc position peaked at $4.43M in Q1 2018.
  • 177 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2018.

Based on Rafferty Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.